Clinical Trial Update: Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study evaluated cetuximab and/or dasatinib in patients with colorectal cancer and liver metastases that could be surgically removed; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Sprycel (dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Liver Metastases, Mucinous Adenocarcinoma of the Colon | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2012-09-07